1. Home
  2. PACB vs TBPH Comparison

PACB vs TBPH Comparison

Compare PACB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PACB
  • TBPH
  • Stock Information
  • Founded
  • PACB 2000
  • TBPH 2013
  • Country
  • PACB United States
  • TBPH United States
  • Employees
  • PACB N/A
  • TBPH N/A
  • Industry
  • PACB Biotechnology: Laboratory Analytical Instruments
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • PACB Industrials
  • TBPH Health Care
  • Exchange
  • PACB Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • PACB 462.1M
  • TBPH 545.0M
  • IPO Year
  • PACB 2010
  • TBPH N/A
  • Fundamental
  • Price
  • PACB $1.32
  • TBPH $11.64
  • Analyst Decision
  • PACB Buy
  • TBPH Strong Buy
  • Analyst Count
  • PACB 9
  • TBPH 5
  • Target Price
  • PACB $2.06
  • TBPH $16.60
  • AVG Volume (30 Days)
  • PACB 7.4M
  • TBPH 165.7K
  • Earning Date
  • PACB 08-07-2025
  • TBPH 08-12-2025
  • Dividend Yield
  • PACB N/A
  • TBPH N/A
  • EPS Growth
  • PACB N/A
  • TBPH N/A
  • EPS
  • PACB N/A
  • TBPH N/A
  • Revenue
  • PACB $152,357,000.00
  • TBPH $65,266,000.00
  • Revenue This Year
  • PACB $3.36
  • TBPH $51.74
  • Revenue Next Year
  • PACB $18.20
  • TBPH N/A
  • P/E Ratio
  • PACB N/A
  • TBPH N/A
  • Revenue Growth
  • PACB N/A
  • TBPH 6.11
  • 52 Week Low
  • PACB $0.85
  • TBPH $7.44
  • 52 Week High
  • PACB $2.72
  • TBPH $11.88
  • Technical
  • Relative Strength Index (RSI)
  • PACB 47.27
  • TBPH 53.45
  • Support Level
  • PACB $1.25
  • TBPH $11.05
  • Resistance Level
  • PACB $1.44
  • TBPH $11.32
  • Average True Range (ATR)
  • PACB 0.13
  • TBPH 0.25
  • MACD
  • PACB -0.03
  • TBPH -0.03
  • Stochastic Oscillator
  • PACB 21.57
  • TBPH 64.40

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: